Investigational drug · Phase 2
HBI-3000
Also called: sulcardine sulfate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atrial Fibrillation.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HBI-3000"
First trial start
2021
Jun 1, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HBI-3000", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atrial Fibrillation
Approved drugs for the same conditions: Atrial fibrillation · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HBI-3000" as an intervention, largest first.
- A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)Pivotal-lookingActive, not recruiting
HUYABIO International, LLC.Industry
NCT04680026 · 150 participants (planned) · Start Jun 1, 2021 · Primary completion Dec 31, 2025
Drug: HBI-3000; Placebo · For: Atrial Fibrillation
Sites: Naples, Florida; Springfield, Illinois; Tupelo, Mississippi · 14 sites in all
- A Phase 1 Study of HBI-3000Completed
HUYABIO International, LLC.Industry
NCT03397641 · 47 participants · Start Oct 17, 2017 · Primary completion Jul 10, 2018
Drug: HBI-3000 · For: Atrial Fibrillation
Sites: Nottingham, United Kingdom
- Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female SubjectsCompleted
HUYABIO International, LLC.Industry
NCT04650542 · 39 participants · Start Feb 21, 2021 · Primary completion Aug 13, 2021
Drug: HBI-3000; Paroxetine · For: Drug-drug Interaction
Sites: West Bend, Wisconsin; Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation.
Mason JW, Romano SJ, Elliott GT, et al. · Heart Rhythm O2 2026
- 26-Week Repeated-Dose Toxicity Study of a Novel Antiarrhythmic Drug Sulcardine Sulfate in Sprague-Dawley Rats.
Zhang L, Gu L, Qiao H · J Appl Toxicol 2025
- Retraction Note: Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
Ren C, Wang Y, Zhang M, et al. · Pharm Res 2023
- Characterization of Preclinical Pharmacokinetic Properties and Prediction of Human PK Using a Physiologically Based Pharmacokinetic Model for a Novel Anti-Arrhythmic Agent Sulcardine Sulfate.
Ren C, Wang Y, Zhang M, et al. · Pharm Res 2021
- Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti-arrhythmic compound.
Chen W, Gan L, Wang Y · Eur J Pharmacol 2019
- Multiple Dose Pharmacokinetics and Safety of Sulcardine Sulfate in Healthy Chinese Male Subjects: An Open-Label Phase I Clinical Study.
Wang W, Qian HJ, Xin L, et al. · Eur J Drug Metab Pharmacokinet 2017
Also in development for Atrial Fibrillation
- MilvexianJNJ-70033093, BMS-986177Phase 33 trials
Johnson & Johnson (Janssen) · Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation, Acute Coronary Syndrome
- BAY 3670549Phase 21 trial
Bayer · Atrial Fibrillation
- PKN605Phase 21 trial
Novartis · Atrial Fibrillation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.